Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Prevention Bio

- PMLiVE

bluebird bio’s sickle cell gene therapy accepted for FDA priority review

The genetic disease affects approximately 100,000 people in the US

- PMLiVE

bluebird bio submits US application for sickle cell gene therapy

The genetic disease affects approximately 100,000 people in the US alone

- PMLiVE

Authorisation for Moderna and Pfizer/BioNTech’s bivalent COVID-19 vaccines simplified by FDA

The vaccines are now authorised for all doses in individuals aged six months and older

- PMLiVE

BioNTech and Duality Biologics partner in deal worth over $1.5bn

The companies will co-develop two antibody-drug conjugates for solid tumours

- PMLiVE

BioNTech reveals plans to spend about €1bn more on research and development this year

The company has already started clinical trials assessing four new infectious disease vaccines

- PMLiVE

Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children

The companies have also submitted an application to the EMA for this age group

- PMLiVE

BioNTech and Weizmann Institute to collaborate at company’s new mRNA centre in Israel

The research facility is expected to start operations by the end of the year

- PMLiVE

Pfizer/BioNTech submit FDA application for Omicron-adapted booster for young children

The vaccine is already authorised as the third of a three-dose primary series in this age group

- PMLiVE

Pfizer/BioNTech initiate study of first mRNA shingles vaccine candidates

Around 95% of people over the age of 50 have been exposed to the virus that causes shingles

- PMLiVE

FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine

Preliminary data showed a possible link between the updated vaccine and a higher risk of stroke

- PMLiVE

BioNTech to acquire UK AI start-up InstaDeep in deal worth over £560m

The deal will enable drug discovery and development of immunotherapies and vaccines

- PMLiVE

BioNTech and UK government partner to accelerate mRNA cancer immunotherapies

The partnership hopes to provide personalised therapies for up to 10,000 patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links